European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2014
Infective complications following tumour endoprosthesis surgery for bone and soft tissue tumours.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peel T, May D, Buising K, Thursky K, Slavin M, Choong P
Аннотация
AIMS: This study aims to describe the incidence of infective complications, including tumour endoprosthesis infection, in a cohort of patients undergoing tumour endoprosthesis surgery in Victoria, Australia.
METHODS: This retrospective cohort study was performed over 15 years (January 1996-December 2010).
RESULTS: 121 patients underwent tumour endoprosthesis surgery during the study period. Patients were followed for a median of 34 months (interquartile range [IQR] 17, 80). Overall, 34 patients (28%) experienced infective complications including: bacteraemia in 19 patients (16%) and tumour endoprosthesis infection in 17 (14%). The majority of patients with early and late acute infections (haematogenous) were managed with debridement and retention of the prosthesis in addition to biofilm-active antibiotics. Late chronic infections were predominantly managed by exchange of the prosthesis. The overall success rate of treatment was 71%. The success rate for debridement and retention was 75% compared with 67% for exchange procedures.
CONCLUSIONS: There is a significant rate of infective complications following tumour endoprosthesis surgery including 14% of patients experiencing infection involving the tumour endoprosthesis. This study is the first to report on outcomes from debridement and retention of the prosthesis; which had comparable success rates to other treatment modalities.
METHODS: This retrospective cohort study was performed over 15 years (January 1996-December 2010).
RESULTS: 121 patients underwent tumour endoprosthesis surgery during the study period. Patients were followed for a median of 34 months (interquartile range [IQR] 17, 80). Overall, 34 patients (28%) experienced infective complications including: bacteraemia in 19 patients (16%) and tumour endoprosthesis infection in 17 (14%). The majority of patients with early and late acute infections (haematogenous) were managed with debridement and retention of the prosthesis in addition to biofilm-active antibiotics. Late chronic infections were predominantly managed by exchange of the prosthesis. The overall success rate of treatment was 71%. The success rate for debridement and retention was 75% compared with 67% for exchange procedures.
CONCLUSIONS: There is a significant rate of infective complications following tumour endoprosthesis surgery including 14% of patients experiencing infection involving the tumour endoprosthesis. This study is the first to report on outcomes from debridement and retention of the prosthesis; which had comparable success rates to other treatment modalities.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overBody Mass IndexBone NeoplasmsChondrosarcomaCohort StudiesCoinfectionFemaleFemoral NeoplasmsGiant Cell Tumor of BoneHistiocytoma, Malignant FibrousHumansHumerusMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedNeoplasms, Connective and Soft TissueOperative TimeOsteosarcomaPelvic BonesProstheses and ImplantsProsthesis ImplantationProsthesis-Related InfectionsRetrospective StudiesRisk FactorsSarcoma, EwingStaphylococcal InfectionsTibiaVictoriaYoung Adult